Cetera Advisor Networks’s Seres Therapeutics MCRB Stock Holding History

Cetera Advisor Networks’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-150	Closed	-$14K	–	2283
2020 Q2	$14K	Buy	+150	New	+$13.2K	﹤0.01%	2575
2017 Q4	–	Sell	-550	Closed	-$176K	–	1003
2017 Q3	$176K	Hold	550	–	–	0.01%	870
2017 Q2	$125K	Hold	550	–	–	0.01%	890
2017 Q1	$125K	Hold	550	–	–	0.01%	888
2016 Q4	$110K	Hold	550	–	–	0.01%	840
2016 Q3	$135K	Buy	+550	New	+$193K	0.01%	996

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cetera Advisor Networks's MCRB Position: Q3 2020 in Review

Cetera Advisor Networks sold out of Seres Therapeutics (MCRB) in Q3 2020, closing a stake of 150 shares — an estimated $14K sold.

Cetera Advisor Networks first reported a position in MCRB in Q3 2016 and held it in 6 quarters. The position peaked at $176K in Q3 2017. 113 funds tracked by Wall St. Rank hold MCRB as of Q3 2020.

Cetera Advisor Networks reported no remaining Seres Therapeutics position as of Q3 2020 after selling out during the quarter.
Cetera Advisor Networks sold 150 Seres Therapeutics shares in Q3 2020, an estimated $14K.
Cetera Advisor Networks first reported a position in Seres Therapeutics in Q3 2016 and held it in 6 quarters.
Cetera Advisor Networks's Seres Therapeutics position peaked at $176K in Q3 2017.
113 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2020.

Based on Cetera Advisor Networks's 13F filing for Q3 2020, filed 13 Nov 2020.